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Abstract
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is an extremely therapy resistant osteomyelitis-like 
disease exclusively involving the jaw bones of patients in treatment with bisphosphonates (BPs).
Objectives: The aim of this study was to evaluate the radiological and clinical findings and management of 51 
patients with BRONJ diagnosed from 2004 to 2009 in our Reference Center.
Study Design: A prospective study was performed. The patients were examined every 2-6 months, depending on 
their clinical conditions. Outcome variables were the resolution of symptoms, persistence of bone exposure and /
or fistula and the status of the lesional mucosa.
Results: The higher prevalence of the disease was noted in 2006 and 2007 and at the time of diagnosis 90% of 
patients had been treated with iv BPs. The main precipitating event leading to BRONJ was an invasive dental 
procedure in 61% of patients while no traumatic event could be identified in 16% of patients. The median time 
of follow-up was 19 months (range: 2-57), during which 31% of patients healed and 39% succumbed. In 78% of 
patients the therapy was medical, in 16% it consisted in surgical deep curettage and only in 6% it was necessary 
to perform an osteotomy to avoid a mandibular pathological fracture. All the patients in treatment with oral BPs 
healed from BRONJ with a median time of conservative treatment of 19 months.
Conclusions: Prevention has lead to a progressive reduction in the prevalence of BRONJ. In our experience medi-
cal treatment is often sufficient to keep the disease under control and to lead to the healing of the lesions by spon-
taneous loss of the sequestrum.
This approach seems to be very effective in patients who were in treatment with oral Bps preparations; BRONJ 
seems to have a more benign clinical behaviour in these patients.
Key words: Bisphosphonates, osteonecrosis, treatment, follow-up.
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Introduction
Bisphosphonate-related osteonecrosis of the jaws 
(BRONJ) is an extremely therapy resistant osteomy-
elitis-like disease exclusively involving the jaw bones 
of patients in treatment with bisphosphonates (BPs). 
The potent nitrogen-containing BPs (e.g. pamidronate, 
zoledronic acid, alendronate, risedronate and ibandro-
nate), predominantly when administered intravenously 
(iv), have been more often associated with this disease. 
The incidence of BRONJ remains undefined and it ran-
ges from 0.8 to 12% for i.v. preparations; the incidence 
for oral preparations ranges from 0,01 to 0,06 % and 
after oral invasive treatments this rate increases from 
0,07 to 0,34% (1-7).
BRONJ is more often localized in the mandible than in 
the maxilla (2:1 ratio), it is usually caused by a dental 
surgical procedure (60-70% of cases) or a prosthetic 
trauma and it is more rarely spontaneous (1-7).
The mechanism of action of bisphosphonates is not yet 
well understood, but it essentially involves a powerful 
inhibition of bone resorption as a result of the reduc-
tion of osteoclast activity; as far as nitrogen-containing 
BPs are concerned they are also thought to have antian-
giogenic effects (8).
The first cases of BRONJ were observed in 2003 and 
all the initial observations have pointed on the potential 
role of the intravenously administered bisphosphonates 
(9-14). Additionally, BRONJ has been reported in a 
small number of patients who had received oral non-
nitrogen or oral nitrogen-containing bisphosphonates 
both in cancerous and non-cancerous conditions.
The aim of this study is to present the clinical and ra-
diological features and the follow-up data of 51 patients 
affected by BRONJ and primarily treated with a con-
servative non- surgical approach.
Material and Methods
From 2004 to 2009 51 patients with BRONJ were ob-
served and prospectively followed at the Reference Center 
for the Study of Oral Diseases, Florence, Italy. The diag-
nosis was performed basing on clinical and radiographic 
features and biopsy was carried out only when necessary 
to exclude other diseases. To stage the lesions were used 
the most authoritative criteria for BRONJ put forth by the 
AAOMS (1,2). In all cases, a panorex or a computerized 
tomography of the jaws was performed. 
In keeping with current published guidelines, all the pa-
tients were initially treated with a conservative approach, 
using nonalcohol-containing chlorhexidine 0.12% mouth 
rinse, local irrigation with povidone-iodine, superficial 
curettage or conservative debridement of bone seques-
tra, intermittent oral antibiotics and pharmacological 
pain control as clinically required (1,2). Conservative 
debridement consisted in a non-aggressive, superficial 
removal of bone sequestra while the goal of superficial 
curettage was to eliminate dead bone, foreign material 
and plaque without exposure of additional bone. The dos-
age of amoxicillin/clavulanate potassium  was  1000 mg 
tabletes every 12h for 15-20 days associated, in resistant 
cases, to 250 mg metronidazole every 8 h for 5 days. In 
penicillin allergic patients 300 mg clindamycin was ad-
ministered three times a day. Pain control was obtained 
by oral administration of nonsteroidal anti-inflammatory 
drugs (nimesulide or ibuprofen) preferably, or opioids 
(tramadol hydrochloride). Surgical treatments (flap oste-
otomy), were performed only when we were unable to 
control the necrosis of the bone, to avoid severe compli-
cations. Hyperbaric oxygen therapy was not used. The 
continuation of bisphosphonate treatment after BRONJ 
was diagnosis was left to the discretion of the treating 
physician. The patients were then examined every 2-6 
months, depending on their clinical conditions.
Results
From 2004 to 2009 51 cases of BRONJ were diagnosed; 
the higher prevalence of the disease was noted in 2006 and 
2007, while the lower one was during 2009. The median 
age of patients was 68 years and the sex ratio was F:M = 
3:2 (30 females and 21 males). At the time of diagnosis, 
46 patients (90% of cases) had been treated with iv BPs 
for oncological reasons for a median of 28 months (range 
3-120) while 5 patients (10%) affected by non-oncologi-
cal diseases were treated with oral BPs for a median of 48 
months (range 24-84) (Table 1). Multiple myeloma was 
the most common oncological disease (31% of cases) fol-
lowed by metastases from breast cancer (27% of cases). 
Thirty-four patients (67%) underwent cancer treatments 
during the year preceding the onset of BRONJ. The onco-
logical treatment modalities in the studied group varied 
widely and included chemotherapeutic agents (alkalyting 
agents, antimetabolites), hormonal treatments (antiandro-
gens, antiestrogens, aromatase inhibitors) and inhibitors 
of angiogenesis (thalidomide).
The precipitating event leading to BRONJ was an inva-
sive dental procedure in 31 patients (61%) that was dental 
extraction in 27 of them (53% of all patients). A prosthetic 
trauma was found in 12 patients (23%) while no traumatic 
event could be identified in 8 patients (16%). The mandi-
ble was affected in 31 patients (61%), the maxilla in 13 pa-
tients (25%), while both jaws were affected in 7 patients 
(14%). The lesions observed were 65 in all, 66% of which 
were mandibular. Using the proposed staging criteria for 
BRONJ, at diagnosis 3 patients (5%) presented with stage 1 
disease, 46 patients (90%) with stage 2, and 2 patients with 
stage 3 (5%). The bisphosphonate treatment was stopped 
by the treating physician in all patients. At diagnosis 20 
patients felt pain (39%), 4 patients (8%) presented trismus 
and one patient (2%) paresthesia (Table 2). The lesions 
most frequently showed as an area of bone exposure (85% 
of lesions) and more rarely a fistula (15% of lesions). 
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Table 1. Epidemiological data of 51 BRONJ pa-
tients.
Primary disease Cases (%)
Multiple myeloma 16 (31%)
Breast cancer 14 (27%)
Prostate cancer 6 (12%)
Osteoporosis 4 (8%)
Lung cancer 4 (8%)
LNH 3 (6%)
Bladder cancer 2 (4%)
Rheumatoid arthritis 1 (2%)
Colon cancer 1 (2%)
BP1 type
Zoledronate 31 (61%)
P and Z2 15 (29%)
Alendronate 4 (8%)
Risedronate 1 (2%)
Cancer therapy3 34 (67%)
BRONJ trigger factors
Tooth extraction 27 (53%)
Prosthetic trauma 12 (23%)
Spontaneous 8 (16%)
Implantology  3 (6%)
Apicectomy 1 (2%)
Median time of i.v. BP1 
administration (range)
28 months
(3-120)
Median time of oral BP1 
administration (range)
54 months 
(24-84)
Table 2. Clinical aspects (65 oral lesions of 51 
BRONJ patients).
Clinical presentation lesions (%)
Exposed bone 55 (85%)
Oral fistula 10 (15%)
Symptoms at diagnosis cases (%)
Pain 20 (39%)
Trismus 4 (8%)
Paresthesia 1 (2%)
Treatment cases (%)
Conservative  40 (78%)
Deep bone curettage 8 (16%)
Jaw resection 3 (6%)
Evolution1 lesions (%)
Stable 27 (42%)
Healing 19 (30%)
Improvement 10 (16%)
Progressive 8 (12%)
Complications cases (%)
Skin fistula  3 (6%)
Oro-antral comunication 2 (4%)
Mandibular fracture 2 (4%)
1) A patient with a lesion lost at follow-up.
1) BP: Bisphosphonate. 2) P and Z:  zoledronate 
preceded by pamidronate administration. 3) Cancer 
therapy performed  within a year of appearance of 
BRONJ.
The median time of follow-up was 19 months (range 
2-57), during which 16 patients (31%) healed while 20 
patients (39%) succumbed from complications related 
to their malignancy; only a fatality could be attributed 
directly to BRONJ complications (mandibular fracture 
and consequent surgical treatment). Only a patient was 
lost to follow-up.
In 40 patients (78%) the therapy was not surgical, while 
in 8 patients (16%) it consisted in surgical deep curet-
tage; only in 3 patients (6%) it was necessary to perform 
an osteotomy to avoid a mandibular pathological frac-
ture. Of the 64 lesions followed (a patient with a lesion 
was lost at follow-up), 42% remained stable (27 lesions), 
16% improved (10 lesions), 30% healed (19 lesions) and 
12% worsened (8 lesions). 
14 of 19 healing lesions  were exclusively treated with a 
conservative approach and healed after spontaneous se-
questrum loss (Table 3), (Figs. 1,2). Necrotic bone loss 
resulted in a fistula which healed after local irrigation 
with saline and povidone-iodine in only 2 cases. The re-
maining  5 healing lesions were treated surgically,  but 
primary healing was observed in 3 cases only ( 2 cases 
treated with osteotomy and 1 case with deep curettage). 
All the patients with BP oral administration healed and 
were exclusively treated  with conservative treatment. 
The most common complication was the appearance of 
a skin fistula (6% of cases) while oro-antral communi-
cations rarely occurred (4% of cases) as well as patho-
logical mandibular fractures (4% of cases) (Figs. 3,4). 
At diagnosis the most common radiographic features of 
the necrotic bone were worm-eaten appearance (32% 
of lesions) followed by superficial osteolysis (24% of 
lesions), while osteolysis was limited to cortical bone 
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Fig. 1. A) Healing after conservative treatment: clinical features at 
diagnosis. B) Spontaneous healing following loss of bone seques-
trum 18 months after diagnosis. C) Sequestrum.
Fig. 2. A) Healing after conservative treatment: radiological features 
at diagnosis. B) Radiological features after 12 mounths. C) Radio-
logical features after 18 mounths  (healing).
Fig. 3. Three years follow-up in a stage 3 patient. Oral lesion and skin fistula at diagnosis and oral lesion after a year.
Fig. 4. Three years follow-up in a stage 3 patient. Oral lesion and skin fistula after 
three years.
BP1 type Cases
Zoledronate 5
P and Z2 6
Alendronate 4
Risedronate 1
Median time from diagnosis 
to healing (months) 22
Location lesions
Anterior mandibula 10
Posterior maxilla 8
Anterior maxilla 1
Treatment lesions
Conservative  14
Deep curettage 3
Jaw resection 2
Modality of healing lesions
Spontaneous loss sequestrum 12
Spontaneous closing  fistula 4
After surgery treatment 3
Table 3. Clinical aspects of the16 healed patients (19 le-
sions).
1) BP: Bisphosphonate. 2) P and Z:  zoledronate preceded 
by pamidronate administration.
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Worm-eaten
appearence
Superficial 
osteolysis1 Deep osteolysis
2 No rx-findings
Non-healing 
extraction 
socket
Sequestrum
16 (32%) 12 (24%) 9 (18%) 6 (12%) 6 (12%) 1 (2%)
Table 4. Radiological findings at diagnosis (50 lesions).
1) radiological lesion involving only cortical bone. 2) radiological lesion involving cortical and midollar bone.
without bone marrow involvement; these radiological 
aspects corresponded to a more favourable clinical con-
dition. In some cases it was not possible to identify any 
radiological lesion (12% of lesions) despite the presence 
of clinical bone exposure (Table 4).
Discussion
Two classes of BPs are in clinical use today: a less potent 
group of non-nitrogen containing molecules (etidronate 
and clodronate) and a newer class of very potent agents 
that contain a nitrogen moiety (pamidronate, zoledronic 
acid, alendronate, risedronate, ibandronate and others). 
Besides bone effects the nitrogen-BPs have antitumoral 
and antiangiogenesis properties, which make them very 
important drugs in the treatment of primary and sec-
ondary bone oncologic disease (15).
Various hypotheses have been proposed about the ae-
tiology of BRONJ but fundamental questions remain 
unanswered. Probably the aetiology is multifactorial, 
where the disruption of bone remodeling, local trau-
ma, pre-existing dental disease, concomitant cancer 
therapies, reduced angiogenesis and superinfection 
lead to a disrupted bone microenvironment prone to 
osteonecrosis. The exact role these different factors 
play in the pathogenetic process remains to be esta-
blished (2,16,17).
Only the mandible and maxilla appear to be suscep-
tible, highlighting their unique nature compared with 
other parts of the skeleton. The jaws are the only bones 
in the human body that are in frequent contact with 
the outside world and are subject to repeated micro-
trauma through the presence of teeth and the forces of 
mastication; moreover the turnover of alveolar bone 
is 10-fold greater   than in the long bones. While BPs 
can decrease this turnover, the alveolar remodeling 
still remained higher compared with the long bones. 
Local trauma caused by tooth extractions, local sur-
gery or ill-fitting dentures are the foremost important 
risk factors, being consistently reported throughout 
the literature (2). 
Apparently there is no clear evidence that the associa-
tion of BPs and a particular cytotoxic agent or class 
of chemotherapic agents increases the risk of BRONJ 
onset. Otherwise, many cases have been reported with 
alkylators alone (2).
According to literature BRONJ mainly affects people 
over 60 years of age and females more often than males; 
diseases that more frequently underlie BRONJ are mul-
tiple myeloma first of all , then, in order of frequency, 
breast cancer , prostate cancer and osteoporosis (2-7).
Approximately 90% of reported BRONJ cases received 
zoledronic or pamidronic acid while the remainder of 
patients were treated with oral bisphosphonates such as 
alendronate or risedronate (2-7).
An always increasing number of cases concerns the 
use of intravenously administered ibandronate, a newer 
agent licensed in the US for the treatment of osteoporo-
sis and also available as an oral formulation.
BRONJ affects the mandible more often than the ma-
xilla, while both jaws involvment is rare.
Over 90% of cases of BRONJ follow a trigger event such 
as a surgical or a prosthetic trauma, while a spontane-
ous onset is rare (2-7). All of these epidemiological data 
are in accordance with those we found.
Diagnosis of BRONJ should be mainly based on clinical 
and radiographic criteria. Tissue biopsy is not always 
necessary and should be performed only if metastatic 
disease is suspected.
American Association of Oral and Maxillofacial Sur-
geons position paper guidelines define the disorder as 
the persistence of exposed bone in the oral cavity in 
patients treated with BPs, after adequate management 
for 8 weeks, in the absence of local metastatic disease 
and without previous radiation therapy to the affected 
area (1,2). 
The clinical aspects and behaviour of BRONJ show a 
striking resemblance to osteoradionecrosis with exposed 
bone and sequestration non-responsive to conventional 
surgical management. BRONJ may be asymptomatic 
for long time or may result in pain or exposed maxi-
llary or mandibular bone. Typical signs and symptoms 
are pain, soft-tissue swelling and infection, loosening 
of teeth and draining fistula. Patients may have other 
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symptoms, which are bred by the infection, such as tris-
mus, halitosis and recurrent abscesses, sinusitis with or 
without oro-antral fistula (2,18). 
Staging criteria for BRONJ have been proposed, bas-
ing on the model of cancer tumour staging. The most 
authoritative to date are those put forth by the AAOMS 
(1,2). The ASBMR (American Society for Bone and 
Mineral Research) task force has recently recommend-
ed the development of a more comprehensive staging 
and grading system that is based not only on physical 
examinations and symptoms but on imaging and other 
parameters as well, in order to better define severity and 
assess treatment response (19).
Complications that may be observed in association to 
BRONJ are, in order of frequency: skin fistula, maxi-
llary sinusitis with oro-antral and/or oro-nasal commu-
nications and pathologic fracture of the mandible.
A panorex is commonly used for the diagnosis of 
BRONJ, but tomographic images are needed to esta-
blish the real extent of bone necrosis and for a more ac-
curate diagnosis of the complications (20,21).
Magnetic resonance imaging, cone-beam computerized 
tomography and nuclear bone scan (PET-TC) have been 
proposed to better identify the osteonecrotic area and 
make an earlier diagnosis (21,22). 
Radiographic alterations are not evident until there is 
significant bone involvement. Late radiographic chang-
es may mimic classic periapical inflammatory lesions 
or osteomyelitis. Other radiographic findings include 
non-healing extraction site, widening of the periodontal 
ligament space and osteosclerotic lamina dura (21).
In our experience the most frequent radiographic as-
pects at the time of diagnosis are worm-eaten like le-
sions (32% of lesions) followed by superficial osteolysis 
(24% of lesions).
Currently there are no effective treatments for BRONJ 
even if a large variety of treatment modalities have 
been reported, including conservative medical man-
agement, various types of surgery, hyperbaric oxygen, 
ozone therapy and laser therapy (2,21,23). The AAOMS 
has proposed a staging system in order to select the 
best treatment strategy for a given patient. Patients 
with stage 1 and 2 BRONJ should be treated using a 
conservative approach with the goal of preventing pro-
gression of lesions and limiting complications related 
to chronic infection (2). To achieve these goals, con-
servative debridement of bone sequestra, local irriga-
tion with povidone-iodine and daily rinsing with 0,12% 
chlorhexidine mouthwash, antibiotic therapy and pain 
control should be considered. Surgical debridement has 
been variably effective in eradicating the necrotic bone. 
The goal of surgery should be to eliminate dead bone 
which acts as foreign material; thus necrotic areas that 
are a constant source of soft tissue irritation should be 
removed or recontoured without exposure of additional 
bone. Recent findings have further confirmed that non-
surgical medical management of BRONJ, consisting in 
long-term administration of antibiotics, is very effec-
tive in controlling the progression of the disease. In case 
of stage 3 patients with pathologic mandibular fractures 
segmental resection and reconstruction are required.
In our experience conservative non surgical manage-
ment is a valid approach to BRONJ considering the poor 
health of BRONJ affected people; in our study conserv-
ative medical management made 42% of BRONJ lesions 
become stable and 30% of them heal spontaneously; we 
observed the healing of the lesions in all the patients 
with BP oral administration.
Five of our patients were destined to segmental resection 
of the mandible; one of these died from surgical complica-
tion, 2 of these healed and the other 2 ones refused surgery 
and have been under conservative treatment without path-
ologic fracture of the mandible occurrence until now.
It is very important that preventive measures are al-
ways taken in order to subvert the risk of developing 
this severe complication. These include careful dental 
examination and preventive extractions of candidate 
teeth with enough time allowed for healing in advance 
of the start of  BPs treatment. Moreover, all patients tak-
ing BPs have to be informed of the benefits and risks 
of treatment and encouraged to maintain good oral hy-
giene (including regular dental visits) (2).
Conclusions
Prevention has lead to a progressive reduction in the 
prevalence of BRONJ. Since BRONJ patients’ poor 
health and uncertainty of surgical outcomes, conserva-
tive management is to be preferred. In our experience 
medical treatment is often sufficient to keep the disease 
under control and to lead to the healing of the lesions by 
spontaneous loss of the sequestrum.
This approach seems to be very effective in patients who 
were treated with oral BP preparations; BRONJ seems to 
have a more benign clinical behaviour in these patients.
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